BiotechTube

Inactivated influenza split vaccine

ApprovedCompleted
0 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Human Influenza

Conditions

Human Influenza

Trial Timeline

Nov 1, 2011 → Mar 1, 2012

NCT ID
NCT01511744

About Inactivated influenza split vaccine

Inactivated influenza split vaccine is a approved stage product being developed by Hualan Biological Engineering for Human Influenza. The current trial status is completed. This product is registered under clinical trial identifier NCT01511744. Target conditions include Human Influenza.

What happened to similar drugs?

13 of 20 similar drugs in Human Influenza were approved

Approved (13) Terminated (4) Active (7)
✅lopinavir/ritonavirAbbVieApproved
✅emtricitabine/tenofovir disoproxil fumarateMerckApproved
✅Human Papillomavirus 9-valent Vaccine, RecombinantMerckApproved
✅3-drug anti-HIV therapy + RaltegravirMerckApproved
✅GardasilMerckApproved
✅RaltegravirMerckApproved
✅RaltegravirMerckApproved

Hype Score Breakdown

Clinical
20
Activity
8
Company
12
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01511744ApprovedCompleted

Competing Products

20 competing products in Human Influenza

See all competitors
ProductCompanyStageHype Score
mRNA-1653ModernaPhase 1
0
mRNA-1653ModernaPhase 1
0
mRNA-1345ModernaPhase 1
0
Influenza vaccine, split inactivatedComac MedicalPhase 1
19
CS-8958 + CS-8958 + oseltamivir phosphateDaiichi SankyoPhase 3
40
GSK1265744 30mg + Placebo + GSK1265744 5mgShionogiPhase 2
35
DolutegravirShionogiPhase 3
40
GSK1349572 + efavirenzShionogiPhase 2
35
Dolutegravir + Rlipivirine + GSK1265744ShionogiPhase 1
29
Dolutegravir 50 mg tablet + Dolutegravir 50 mg oral granulesShionogiPhase 1
29
Dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg + Dolutegravir 50 mg + abacavir 600 mg/lamivudine 300 mgShionogiPhase 1
29
GSK1349572 (dolutegravir) + raltegravirShionogiPhase 3
40
Ortho-Cyclen + Dolutegravir + PlaceboShionogiPhase 1
29
GSK1349572 + Placebo + Iohexol Injection + Para-aminohippurate infusionShionogiPhase 1
29
dolutegravirShionogiPhase 3
40
Dolutegravir + Atripla + Abacavir/Lamivudine + Abacavir/Lamivudine Placebo + Dolutegravir placebo + Atripla placeboShionogiPhase 3
40
GSK1349572 + EfavirenzShionogiPhase 1
29
GSK1349572ShionogiPhase 1
29
GSK1349572 + PlaceboShionogiPhase 2
35
Dolutegravir + MethadoneShionogiPhase 1
29